European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security
SNMMI 2018
The European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security is currently developing the application of alpha emitting radionuclides for cancer treatment ("targeted alpha therapy or TAT") for the benefit of cancer patients in Europe and worldwide. JRC is taking actively part to the progressing of the treatment from bench to bedside, including the development of methods to secure the supply of alpha emitters, preclinical research in vitro and in vivo and in particular the clinical testing of novel promising compounds.
Recently JRC has achieved a major breakthrough through the development and clinical application of a novel radiopharmaceutical for treatment of prostate cancer: 225 Actinium-PSMA617
